AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investorsMarket Watch • 11/05/24
AstraZeneca sheds £15bn in value as weight loss drug data ‘underwhelming'Proactive Investors • 11/05/24
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerBusiness Wire • 10/30/24
AstraZeneca positioned for success in key breast cancer drug trials, says leading US investment bankProactive Investors • 10/25/24
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic DisorderBenzinga • 10/24/24
Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 DiabetesGlobeNewsWire • 10/23/24
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/09/24
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and BayerZacks Investment Research • 10/08/24
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching24/7 Wall Street • 10/07/24